OBJECTIVES AND METHODS: Brucellosis is characterized by chronicity and relapses despite efficacious treatment. Cytokines and especially the Th1/Th2 balance may be involved in the susceptibility or resistance to the Brucella species. In order to identify predictors of treatment outcome, we measured the pre and posttreatment levels of serum interleukin-2 (IL-2) and soluble IL-2 receptor alpha (sIL-2Ralpha) in 20 children with brucellosis. All children were treated for 6 weeks and three of them (15%) presented with a relapse at 2, 3 and 8 months after treatment had ended. RESULTS: Serum IL-2 levels, both pretreatment and posttreatment, did not significantly differ between patients and controls. By contrast, pretreatment sIL-2Ralpha levels were significantly higher in patients (P< or =0.0001) than in controls. sIL-2Ralpha levels significantly declined (P<0.001) after the 6-week antibiotic regimen in the 17 children who subsequently had a good outcome without relapses, but not in the three patients who relapsed. CONCLUSIONS: A decline in serum sIL-2Ralpha levels might be used as a marker of treatment efficacy in brucellosis.
OBJECTIVES AND METHODS: Brucellosis is characterized by chronicity and relapses despite efficacious treatment. Cytokines and especially the Th1/Th2 balance may be involved in the susceptibility or resistance to the Brucella species. In order to identify predictors of treatment outcome, we measured the pre and posttreatment levels of serum interleukin-2 (IL-2) and soluble IL-2 receptor alpha (sIL-2Ralpha) in 20 children with brucellosis. All children were treated for 6 weeks and three of them (15%) presented with a relapse at 2, 3 and 8 months after treatment had ended. RESULTS: Serum IL-2 levels, both pretreatment and posttreatment, did not significantly differ between patients and controls. By contrast, pretreatment sIL-2Ralpha levels were significantly higher in patients (P< or =0.0001) than in controls. sIL-2Ralpha levels significantly declined (P<0.001) after the 6-week antibiotic regimen in the 17 children who subsequently had a good outcome without relapses, but not in the three patients who relapsed. CONCLUSIONS: A decline in serum sIL-2Ralpha levels might be used as a marker of treatment efficacy in brucellosis.
Authors: Matthew B Wallenstein; Laura L Jelliffe-Pawlowski; Wei Yang; Suzan L Carmichael; David K Stevenson; Kelli K Ryckman; Gary M Shaw Journal: J Matern Fetal Neonatal Med Date: 2015-12-23
Authors: Lisa M Maier; David E Anderson; Christopher A Severson; Clare Baecher-Allan; Brian Healy; David V Liu; K Dane Wittrup; Philip L De Jager; David A Hafler Journal: J Immunol Date: 2009-02-01 Impact factor: 5.422
Authors: H W van Steenbergen; J A B van Nies; A Ruyssen-Witrand; T W J Huizinga; Al Cantagrel; F Berenbaum; A H M van der Helm-van Mil Journal: Arthritis Res Ther Date: 2015-09-08 Impact factor: 5.156
Authors: Lisa M Maier; Christopher E Lowe; Jason Cooper; Kate Downes; David E Anderson; Christopher Severson; Pamela M Clark; Brian Healy; Neil Walker; Cristin Aubin; Jorge R Oksenberg; Stephen L Hauser; Alistair Compston; Stephen Sawcer; Philip L De Jager; Linda S Wicker; John A Todd; David A Hafler Journal: PLoS Genet Date: 2009-01-02 Impact factor: 5.917
Authors: Todd M Brusko; Clive H Wasserfall; Maigan A Hulme; Roniel Cabrera; Desmond Schatz; Mark A Atkinson Journal: PLoS One Date: 2009-11-24 Impact factor: 3.240
Authors: Kristyn E Feldman; Paul M Loriaux; Mayuko Saito; Iskra Tuero; Homarh Villaverde; Tenaya Siva; Eduardo Gotuzzo; Robert H Gilman; Alexander Hoffmann; Joseph M Vinetz Journal: PLoS Negl Trop Dis Date: 2013-09-05